- Home
- DAWN vs RCKT Comparison
DAWN vs RCKT Comparison
Compare DAWN & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- RCKT
- Stock Information
- Founded
- DAWN 2018
- RCKT 1999
- Country
- DAWN United States
- RCKT United States
- Employees
- DAWN N/A
- RCKT N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- DAWN Health Care
- RCKT Health Care
- Exchange
- DAWN Nasdaq
- RCKT Nasdaq
- Market Cap
- DAWN 1.2B
- RCKT 1.1B
- IPO Year
- DAWN 2021
- RCKT N/A
- Fundamental
- Price
- DAWN $8.07
- RCKT $7.59
- Analyst Decision
- DAWN Strong Buy
- RCKT Strong Buy
- Analyst Count
- DAWN 7
- RCKT 10
- Target Price
- DAWN $32.29
- RCKT $44.10
- AVG Volume (30 Days)
- DAWN 1.3M
- RCKT 1.6M
- Earning Date
- DAWN 05-05-2025
- RCKT 05-05-2025
- Dividend Yield
- DAWN N/A
- RCKT N/A
- EPS Growth
- DAWN N/A
- RCKT N/A
- EPS
- DAWN N/A
- RCKT N/A
- Revenue
- DAWN $131,161,000.00
- RCKT N/A
- Revenue This Year
- DAWN $28.72
- RCKT N/A
- Revenue Next Year
- DAWN $73.78
- RCKT N/A
- P/E Ratio
- DAWN N/A
- RCKT N/A
- Revenue Growth
- DAWN N/A
- RCKT N/A
- 52 Week Low
- DAWN $7.88
- RCKT $7.48
- 52 Week High
- DAWN $18.07
- RCKT $26.99
- Technical
- Relative Strength Index (RSI)
- DAWN 36.05
- RCKT 34.04
- Support Level
- DAWN $7.93
- RCKT $8.22
- Resistance Level
- DAWN $8.44
- RCKT $8.80
- Average True Range (ATR)
- DAWN 0.44
- RCKT 0.48
- MACD
- DAWN 0.09
- RCKT -0.02
- Stochastic Oscillator
- DAWN 17.59
- RCKT 7.72
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.